Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Second Phase III Study Shows Incyte and Novartis Drug Reduces Spleen Size in Myelofibrosis

Partners plan regulatory filings for ruxolitinib in EU and U.S. later this year.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »